Related Experiment Videos
Slow-release gallopamil evaluated by exercise test and long-term electrocardiography
G Steinbeck1, E Reuschel-Janetschek
1Medizinische Klinik I, Universität München, Klinikum Grosshadern, Germany.
Journal of Cardiovascular Pharmacology
|January 1, 1992
Summary
Slow-release gallopamil effectively reduced myocardial ischemia in patients with coronary artery disease. This treatment improved exercise tolerance and decreased ischemic episodes, showing anti-ischemic effects.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Coronary artery disease (CAD) and angina pectoris remain significant health concerns.
- Myocardial ischemia, both exercise-induced and spontaneous, is a key manifestation of CAD.
Purpose of the Study:
- To evaluate the anti-ischemic effects of slow-release gallopamil in patients with CAD and angina.
- To assess the impact of gallopamil on exercise capacity and spontaneous myocardial ischemia.
Main Methods:
- A 48-hour long-term electrocardiography (ECG) monitoring was performed in 26 patients with CAD and angina pectoris.
- Patients received slow-release gallopamil (100 mg b.i.d.).
- Exercise tolerance was assessed using bicycle ergometry, and spontaneous ischemic episodes were analyzed.
Main Results:
- Gallopamil increased exercise workload and duration until ST-segment depression.
- The number and duration of spontaneous myocardial ischemic episodes significantly decreased.
- Three patients experienced asymptomatic second-degree atrioventricular block (Wenckebach type); no other adverse effects were noted.
Conclusions:
- Preliminary results suggest slow-release gallopamil demonstrates anti-ischemic effects in patients with CAD and angina.
- Further confirmation is needed through the double-blind, placebo-controlled phase of the trial.